BioSpace News Archive

Wellin Inc., a natural healthcare company dedicated to pain relief, today announced a newly released clinical study reporting that its over-the-counter pain reliever product Keriflex™ successfully reduces chronic knee, neck and lower back discomfort caused by inflammation in the body and improves overall joint health by 35%

Awareness of Risks with Prescription Pain Medications is Key to Addressing Epidemic

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis (“Novartis”)

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in Europe under the brand name Betadine BVTM

CryoTherapeutics GmbH and CryoTherapeutics SA today announced the closing of its B round of financing.

On June 27, 2019, the global leading chemical company BOC Sciences announced to establish a medicinal chemistry branch, which is specially designed to support scientists’ needs arising from drug discovery efforts, covering nearly the whole process of a drug discovery project from lead discovery all the way to formulation issues.

MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today the launch of Automatiqc™ (pronounced: automatic

OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, announced continuous strong data from a two-year interim analysis of its Phase 2 study with Oxabact® in PH.